Results from a phase I trial at Memorial Sloan Kettering Cancer Center suggest that treatment with mRNA vaccines (autogene cevumeran) cause an effective and lasting immune response in some patients with pancreatic cancer.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.
